Skip to main content

Treatment Clinical Trials for Ewing Sarcoma

Review the Ewing sarcoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 28

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Active
Location: 20 locations
Donor NK Cell Therapy in Combination with Gemcitabine and Docetaxel for the Treatment of Relapsed or Refractory Sarcomas, The TINKS Trial
Status: Active
Location: 16 locations
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status: Active
Location: 12 locations
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Status: Active
Location: 11 locations
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Status: Active
Location: 8 locations
Cabozantinib to Prevent Progression or Recurrence in Patients with High-Risk Pediatric Solid Tumors
Status: Active
Location: 6 locations
Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study
Status: Active
Location: 6 locations
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Location: 4 locations
Lurbinectedin for the Treatment of Patients with Relapsed FET-Fused Tumors
Status: Active
Location: 4 locations
PEEL-224, Vincristine and Temozolomide for the Treatment of Adolescents and Young Adults with Relapsed or Refractory Sarcomas
Status: Active
Location: 3 locations
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Location: 3 locations
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Status: Active
Location: 3 locations
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Status: Active
Location: 3 locations
Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) for the Treatment of Children and Young Adults with Relapse or Refractory Neuroblastoma, Soft Tissue Sarcoma, Osteosarcoma, Ewing Sarcoma, and Wilms Tumor
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Teenagers or Young Adults with Recurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, or Soft Tissue Sarcoma
Status: Active
Location: 4 locations
DFMO Maintenance for the Treatment of Patients with Relapsed Ewing Sarcoma or Osteosarcoma
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Modified Donor Peripheral Blood Stem Cells in Combination with Zoledronic Acid for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Cabozantinib Plus High-Dose Ifosfamide for the Treatment of Relapsed or Refractory Ewing Sarcoma and Osteosarcoma, CaIRS Trial
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Status: Active
Location: 2 locations
A Study of EGFR806 CAR T-Cell Immunotherapy for Treating Children and Young Adults with Recurrent/Refractory Solid Tumors
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Tumor Infiltrating Lymphocytes for the Treatment of Children with High Risk Solid Tumors
Status: Active
Location: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov